

Date 23/02/2026  
Your Ref  
Our Ref 11087

Enquiries to Richard Mutch  
Extension 35687  
Direct Line 0131 465 5687  
[loth.freedomofinformation@nhs.scot](mailto:loth.freedomofinformation@nhs.scot)  
[richard.mutch@nhs.scot](mailto:richard.mutch@nhs.scot)

Dear

## FREEDOM OF INFORMATION – CHRONIC LYMPHOCYTIC LEUKAEMIA

I write in response to your request for information in relation to Chronic Lymphocytic Leukaemia.

Question:

1. How many patients has your Trust treated in the past 12 months (January - December 2025) for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Trust do you refer patients needing treatment to?

Answer:

There were 118 patients.

Question:

2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated by the Trust in the past 6 months on the following treatments:

- BR (bendamustine + rituximab)
- Brukinsa (zanubrutinib)
- Calquence (acalabrutinib)
- Calquence (acalabrutinib) + Gazyva (obinutuzumab)
- Calquence (acalabrutinib) + Venclyxto (venetoclax)
- Calquence (acalabrutinib) + Venclyxto (venetoclax) + Gazyva (obinutuzumab)
- FCR (fludarabine + cyclophosphamide + rituximab)
- Fludarabine Monotherapy
- Gazyva (obinutuzumab) + chlorambucil
- Imbruvica (ibrutinib)
- Venclyxto (venetoclax)
- Venclyxto (venetoclax) + Gazyva (obinutuzumab)
- Venclyxto (venetoclax) + rituximab
- Zydelig (idelalisib) + rituximab
- Imbruvica (ibrutinib) + Venclyxto (venetoclax)
- Any other systemic anti-cancer therapy

Headquarters  
Mainpoint  
102 West Port  
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE  
Chief Executive Professor Caroline Hiscox  
*Lothian NHS Board is the common name of Lothian Health Board*

Answer:

BR (bendamustine + rituximab) 0  
 Brukinsa (zanubrutinib) 8  
 Calquence (acalabrutinib) 30  
 Calquence (acalabrutinib) + Gazyva (obinutuzumab) 0  
 Calquence (acalabrutinib) + Venclyxto (venetoclax) 0  
 Calquence (acalabrutinib) + Venclyxto (venetoclax) + Gazyva (obinutuzumab) 0  
 FCR (fludarabine + cyclophosphamide + rituximab) 0  
 Fludarabine Monotherapy 0  
 Gazyva (obinutuzumab) + chlorambucil 0  
 Imbruvica (ibrutinib) 22  
 Venclyxto (venetoclax) 30  
 Venclyxto (venetoclax) + Gazyva (obinutuzumab) 14  
 Venclyxto (venetoclax) + rituximab 5 or fewer  
 Zydelig (idelalisib) + rituximab 5 or fewer  
 Imbruvica (ibrutinib) + Venclyxto (venetoclax) 5 or fewer  
 Any other systemic anti-cancer therapy 5 or fewer

To protect the identity of the individuals involved any figure of 5 or less has not been shown above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

Question:

3. How many Chronic Lymphocytic Leukaemia (CLL) patients have received treatment for relapsed/refractory CLL in the past 6 months with the following:

- Brukinsa (zanubrutinib)
- Calquence (acalabrutinib)
- Imbruvica (ibrutinib)
- Venclyxto (venetoclax)
- Zydelig (idelalisib) + rituximab
- Any other systemic anti-cancer therapy

Answer:

This is not held in a centrally extractable format and requires data linkage. Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files relating to patients over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost

Question:

4. If your Trust does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any ongoing clinical trials for the treatment of CLL? If yes, please can you provide details of the ongoing trials.

Answer:

There are currently no trials taking place in NHS Lothian for the treatment of Chronic Lymphocytic Leukaemia (CLL)

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at [www.itspublicknowledge.info/Appeal](http://www.itspublicknowledge.info/Appeal). If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director, Nursing**  
Cc: Chief Executive